29-31 January, 2019

Paris, France

REGISTER INTEREST HERE

Event Guide

  • 2018 On-Site Event Guide

    The 2nd Annual Microbiome Drug Development Summit Europe is the only end-to-end meeting designed exclusively for industry leaders to help accelerate the precise translation of microbiome R&D from disease causation into safe, effective and commercially scalable therapeutic products.

    Download the full event guide for:

    ■ A detailed overview of the content of each speaker’s presentation

    ■ Additional insight into the interactive pre-conference workshop sessions focused on Gene Therapy For the Microbiome and Harnessing the Skin Microbiome to Treat Disease

    ■ Additional insight into the interactive post-conference Focus Day on Microbiome for Immuno-Oncology

    What Microbiome Drug Development Summit Europe speakers are looking forward to:

    Mike

    “Catching up on progress in the role of microbiota in drug response”

    “I am excited about catching up on progress in the role of microbiota in drug response and in hearing the latest on bacterial therapeutic development.”

    Mike Romanos, CEO, Microbiotica

    lee

    Emerging microbiome space from the experts

    “I am looking forward to gaining insight into the most recent events shaping the fast paced and emerging microbiome space from the experts gathered at the MDDS as well as sharing our experience in the development of a leading microbiota therapeutic.”

    Lee Jones, Chief Executive Officer, Rebiotix

    Daniel

    “Define the next generation of live bio therapeutic products

    “I am the most excited to meet with my peers and discuss the latest scientific developments that are going to allow us to define the next generation of live bio therapeutic products.”

    Daniel van der Lelie, Chief Scientific Officer, Gusto Global

    Kristin

    “Clarity on the appropriate regulatory pathways”

    “I’m excited to see more clarity on the appropriate regulatory pathways and understand where industry are in the discussions with global regulatory authorities.”

    Kristin Wannerberger, Director, R&D Alliance Management, Ferring Pharmaceuticals

    Lars

    Impact on drug development and future possibilities

    “As a leader of an academic human microbiome research center I very much look forward to see if and how our translational research activities will have an impact on drug development and future possibilities for interventional studies in our well-defined patient cohorts.”

    Lars Engstrand, MD – Professor, Karolinska Institutet

    Christian

    “Effectively leverage the microbiome for human health”

    “I’m looking forward to getting together with the microbiome community to discuss novel therapies and how to effectively leverage the microbiome for human health.”

    Christian Furlan Freguia, Director Of Research, Synthetic Biologics

    Todd

    “Bringing novel microbiome therapies”

    “I want to discuss the challenges of bringing novel microbiome therapies to clinical trials with other thought leaders in the field.”

    Todd Parsley, Chief Scientific Officer, SynPhaGen LLC

    Massimo

    “Support the microbiome community”

    “l’m looking forward to explain how we can support the microbiome community in developing evidence-based LBPs.”

    Massimo Marzorati, Chief Business Development Officer, ProDigest

    bernhard

    Discussing the latest developments

    “I am most looking forward to discussing the latest developments over a refreshing drink with the other participants.”

    Bernhard Paetzold, Chief Scientific Officer, S-Biomedic

     

    download